Intrinsic Value

The intrinsic value of DaVita Inc (TRL) under the Base Case is 197.69 EUR per share. Compared with the current market price of 161.6 EUR, the stock appears Undervalued by 18% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

TRL Intrinsic Value
€197.69
Undervaluation 18%
Intrinsic Value
Price €161.6

TRL is valued in line with its history. A discount of this size has been typical over the past 5 years.

Monitor TRL
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €158.15
Get notified when the price drops into your buy zone
Intrinsic Value €197.69
Current Price €161.6
Margin of Safety 20% €158.15
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to TRL

Fundamental Analysis

What DaVita Does

Health Care

DaVita is a healthcare company focused on kidney care. Its main business is running dialysis centers, where it treats patients whose kidneys can no longer clean waste from the blood properly. It also offers related care services for people with chronic kidney disease, including support before dialysis starts and help managing long-term treatment.

Headquarters
United States of America US
Employees
78 000
IPO date
Oct 31, 1995
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
DaVita Inc

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

DVA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one TRL stock?

The intrinsic value for DaVita Inc (TRL) under the Base Case is 197.69 EUR.

Is TRL stock undervalued or overvalued?

Compared with the current market price of 161.6 EUR, the stock appears Undervalued by 18% .

Back to Top